ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,321.41
      0.25%
      US Tech 100
      18,237.20
      0.03%
      Dow Jones
      39,872.99
      0.17%
      Brent Oil
      81.665
      -0.95%
      Bitcoin
      69,886.41
      -0.35%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Mesoblast Limited (MESO)

      7. Mesoblast Limited (MESO) News

      MESO

      Mesoblast (MESO)

      Mesoblast Limited
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:MESO
      DateTimeSourceHeadlineSymbolCompany
      04/29/20249:05PMGlobeNewswire Inc.Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024NASDAQ:MESOMesoblast Limited
      03/26/20249:25AMAllPennyStocks.comFDA Commentary Sends Biotech Soaring During Premarket HoursNASDAQ:MESOMesoblast Limited
      03/25/202410:34PMGlobeNewswire Inc.United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)NASDAQ:MESOMesoblast Limited
      03/13/20247:30PMGlobeNewswire Inc.Mesoblast Successfully Completes Placement and Accelerated Entitlement OfferNASDAQ:MESOMesoblast Limited
      03/10/20247:54PMGlobeNewswire Inc.United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)NASDAQ:MESOMesoblast Limited
      02/28/20245:57PMGlobeNewswire Inc.Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023NASDAQ:MESOMesoblast Limited
      02/26/20247:00AMGlobeNewswire Inc.Mesoblast Financial Results and Corporate Update WebcastNASDAQ:MESOMesoblast Limited
      02/14/20247:46PMGlobeNewswire Inc.United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart DiseaseNASDAQ:MESOMesoblast Limited
      01/31/20249:34PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MESOMesoblast Limited
      01/30/20249:13PMGlobeNewswire Inc.Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023NASDAQ:MESOMesoblast Limited
      01/18/20247:28PMDow Jones NewsMesoblast Gets FDA's Special Pediatric Designation for Revascor Heart TreatmentNASDAQ:MESOMesoblast Limited
      01/18/20246:36PMGlobeNewswire Inc.United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart DiseaseNASDAQ:MESOMesoblast Limited
      01/16/20246:33AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MESOMesoblast Limited
      01/04/20249:57PMEdgar (US Regulatory)Form F-6 POS - Post-effective amendments for immediately effective filingNASDAQ:MESOMesoblast Limited
      12/22/20235:13PMEdgar (US Regulatory)Form F-6 POS - Post-effective amendments for immediately effective filingNASDAQ:MESOMesoblast Limited
      11/26/20236:56PMGlobeNewswire Inc.Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart DiseaseNASDAQ:MESOMesoblast Limited
      11/22/20231:35PMAllPennyStocks.comBiotech Shares Soar Following Major AnnouncementNASDAQ:MESOMesoblast Limited
      11/22/20231:35PMAllPennyStocks.comBiotech Shares Soar Following Major AnnouncementNASDAQ:MESOMesoblast Limited
      11/21/20236:32PMGlobeNewswire Inc.Mesoblast Partners With Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults With SR-aGVHDNASDAQ:MESOMesoblast Limited
      10/30/20238:04PMGlobeNewswire Inc.Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2023NASDAQ:MESOMesoblast Limited
      09/26/20236:18AMGlobeNewswire Inc.Jane Bell AM Appointed Chair of Mesoblast Audit and Risk CommitteeNASDAQ:MESOMesoblast Limited
      09/21/20233:30AMGlobeNewswire Inc.Key Outcomes From FDA Type A Meeting and Mesoblast Next Steps to Achieve RYONCIL ApprovalNASDAQ:MESOMesoblast Limited
      09/06/20236:42AMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MESOMesoblast Limited
      08/30/20237:07PMGlobeNewswire Inc.Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2023NASDAQ:MESOMesoblast Limited
      08/29/20237:00AMGlobeNewswire Inc.Mesoblast Financial Results and Corporate Update WebcastNASDAQ:MESOMesoblast Limited
      08/04/20239:03AMDow Jones NewsMesoblast ADSs Plunge Premarket on Latest FDA RejectionNASDAQ:MESOMesoblast Limited
      08/03/20238:10PMGlobeNewswire Inc.Mesoblast Receives Complete Response From U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in ChildrenNASDAQ:MESOMesoblast Limited
      07/30/20238:31PMGlobeNewswire Inc.Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2023NASDAQ:MESOMesoblast Limited
      06/06/20238:46AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:MESOMesoblast Limited
      06/04/20238:21PMGlobeNewswire Inc.Mesoblast Director Philip R. Krause, M.D., Appointed to Strategic Advisory RoleNASDAQ:MESOMesoblast Limited
       Showing the most relevant articles for your search:NASDAQ:MESO

      Your Recent History

      USOTC
      CLIS
      ClickStream (CE)
      Delayed Upgrade Clock